Interviews

Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.

David DiBardino, MD, explains how a hafnium compound is being tested alongside chemoradiation and durvalumab to address low response rates in locally advanced disease.

AI streamlines oncology workflows, cuts admin burden, and hints at smarter interoperability—linking fragmented records for quicker clinical decisions.

David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.

E. Anders Kolb, MD, on blood cancer research's legacy in oncology and the racial, geographic barriers still limiting patient access to care.

Saro Armenian, DO, MPH, explains the importance of screening for issues such as secondary skin cancers in patients who received stem cell transplant.

Geoffrey Y. Ku, MD, discusses MATTERHORN, which established perioperative durvalumab plus FLOT as standard care for resectable gastric/GEJ adenocarcinoma.

Manojkumar Bupathi, MD, MS, discusses the changes that biomarker-based treatment brings to hormone-sensitive prostate cancer.

Jeff Sharman, MD, discusses bispecific antibodies, CAR T-cell therapy, and targeted agents reshaping non-Hodgkin lymphoma treatment.

Drs Aditya Shreenivas and Razelle Kurzrock break down a 200,000-tumor real-world study on HER2 IHC, ERBB2 alterations, and pan-cancer testing implications.

MSOs and physician networks streamline oncology practice operations, cut administrative burden, and preserve autonomy—helping community oncologists focus on patients and reduce burnout.

A single blood draw 3 to 9 weeks into immunotherapy predicted survival outcomes in metastatic non–small cell lung cancer, according to a new Johns Hopkins study.

Gavin Wright, MBBS, explains what the phase 3 VISUALIZE 2 trial aims to confirm about abenacianine's surgical benefit for patients with lung cancer.

David DiBardino, MD, explains why intratumoral therapy emerged in lung cancer and the open questions in standardizing how it's delivered to tumors.

Jonathan Villena-Vargas, MD, explains how a subcostal robotic approach avoids intercostal nerve damage, cutting pain post thoracotomy and reducing opioid use.

Oncologists share practical ways to spot burnout early, set boundaries, boost recognition, and protect work-life balance across your career.

Geoffrey Y. Ku, MD, explains the latest developments with bispecific antibodies in patients with gastric and gastroesophageal junction cancers.

For Prostate Cancer Awareness Month, Manojkumar Bupathi, MD, MS, examines how oncologists are changing practice after 4 key FDA approvals and a trend toward biomarker-driven therapy.

Learn why "life years saved" better captures progress in blood cancer than 5-year survival rates, with insights from Dr. E. Anders Kolb of Blood Cancer United.

Manojkumar Bupathi, MD, MS, discusses the key trials that have made a splash in prostate cancer in the last year.

Purpose-built, decentralized oncology trials bring new therapies to community clinics, expanding access and showing trials aren’t just a last resort.

Geoffrey Y. Ku, MD, highlights ongoing advances in gastric/GEJ treatment.

A City of Hope study found success in promoting skin cancer screening to transplant survivors, Saro Armenian, MD, explains.

Gavin Wright, MBBS, discusses how the tumor-targeted imaging agent abenacianine helped surgeons locate hard-to-find tumors in the phase 2b VISUALIZE trial.

New data set reveals Asian American breast cancer survival advantage persists despite reproductive, lifestyle, neighborhood, and treatment factors, highlighting crucial ethnic and nativity differences.

Ryan Funk, MD, explains how 2026 CMS coding changes and commercial payer contracts are straining radiation oncology practices, threatening rural and freestanding centers and patient access to care.

Dr Shubham Pant outlines what's next for daraxonrasib in pancreatic cancer, including the RASolute 303 and RASolute 304 trials.

Next-gen T‑cell immunotherapies tackle resistance and expand access, as bispecifics, trispecifics, and off‑the‑shelf or in vivo CAR T-cell therapies move earlier.

Surbhi Sidana, MD, discusses the ongoing trials that could expand the use of iberdomide into various combinations and settings in patients with multiple myeloma.

System barriers like interoperability gaps, prior authorization delays, and reimbursement pressures intensify oncology physician burnout, disrupting care coordination and straining community practices.